Beware of the spillover effect regarding the endorsement of 12 measures for coordination of care last month by the National Quality Forum. The measures focus on areas such as medication reconciliation, proper use of the ED, and timely initiation of care.

“The NQF has a special line to/relationship with Medicare, so anything recommended by NQF is likely to percolate over to Medicare fee-for-service as another measurement headache for participating hospitals/providers,” says Jaan Sidorov, MD, a consultant and member of Managed Care’s editorial board.

“They’re also likely to spill into Medicare Advantage, which doesn’t use HEDIS.... So this is a heads-up and a warning about what’s around the corner for MA plans.”

Here are the 12 measures and the organizations they came from:

  • Medication reconciliation (NCQA)
  • Admission into an acute-care hospitalization based on risk (CMS)
  • Proper use of emergency department without hospitalization (CMS)
  • An advance care plan (NCQA)
  • Surveys to measure quality of medical home care (NCQA)
  • Timely initiation of care (CMS)
  • Medication review when caring for older adults (NCQA)
  • Medication reconciliation after discharge (NCQA)
  • Reconciled medication list given to discharged patients (AMA)
  • Transition record with specified elements given to patients discharged from an inpatient facility (AMA)
  • Transition record given promptly to patients discharged from an inpatient facility (AMA)
  • Transition record with specified elements given to patients discharged from an emergency department (AMA)

Donald Casey Jr., MD, MPH, MBA, co-chairman of the NQF’s Care Coordination Steering Committee, says that the goals are “developing and implementing a proactive and patient-centered plan of care; effective communication between patients, families, and caregivers; efficient information systems that support timely communication; and transitions of care that promote safe, evidence-based care.”

Richard J. Stefanacci, DO, MBA, the chief medical officer of the Access Group who is also a member of Managed Care’s editorial advisory board, says that NQF’s announcement “adds positive movement toward a critical improvement effort.”

Stefanacci adds that “Striving for these measures will reduce costs for health plans, and the NQF is a recognized authority so these measures are recognized as having value.”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.